Treatment of respiratory tract infections with ciprofloxacin

Area of Science:

• Pharmacology
• Infectious Diseases
• Clinical Medicine

Background:

• Respiratory infections pose a significant health burden.
• Broad-spectrum antibiotics are crucial for treating diverse bacterial pathogens.
• Ciprofloxacin is a fluoroquinolone antibiotic with known antibacterial properties.

Purpose of the Study:

• To evaluate the efficacy and safety of oral ciprofloxacin for respiratory infections.
• To assess the clinical cure rates associated with ciprofloxacin treatment.
• To identify potential adverse drug reactions and interactions.

Main Methods:

• A study involving 129 patients with respiratory infections.
• Oral administration of ciprofloxacin at 750 mg twice daily.
• In-vitro testing to determine antibacterial spectrum.
• Clinical monitoring for treatment outcomes and side effects.

Main Results:

• Ciprofloxacin demonstrated broad in-vitro activity against Gram-negative and Gram-positive bacteria.
• A high clinical cure rate of 96% was achieved.
• The primary adverse event noted was interaction with theophylline, particularly in elderly patients.

Conclusions:

• Oral ciprofloxacin is highly effective in treating respiratory infections.
• The drug exhibits a favorable safety profile, with theophylline interaction being the main concern.
• Further research may be warranted to explore management strategies for drug interactions in specific populations.